Cerevance

We’re proud to be featured in UPMC Enterprises’ 2024 Year in Review, showcasing our continued progress towards our mission of transforming care for patients with central nervous system (CNS) disorders. ? This year, we achieved significant momentum with an additional $47 million raised in our Series B-1 Extension. These funds are propelling our development of cell-type specific therapies for CNS disorders, with a particular focus on advancing our Phase 3 clinical trial for solengepras (CVN424), a potentially first-in-class, oral, non-dopaminergic investigational therapy for Parkinson’s disease. ? Since joining the UPMC Enterprises portfolio in 2020, we’ve continued to build on our commitment to address other CNS challenges, working on potential treatments for Alzheimer’s disease, ALS, and frontotemporal dementia. ? We’re grateful for the support of UPMC Enterprises and our partners and their commitment and belief in our vision. https://lnkd.in/eJGsEHri

#ICYMI Last week, NeurologyLive featured the exciting milestone of dosing the first patient in our Phase 3 ARISE trial of solengepras (CVN424) for the?potential?treatment of Parkinson's disease. Check out the full article here to learn more about ARISE and our efforts to deliver transformative therapies to individuals with PD: https://lnkd.in/eyVzfyWt

We're very pleased to share that we have dosed the first patient in our pivotal?Phase 3 ARISE trial of solengepras (CVN424) for the?potential?treatment of Parkinson's Disease. The trial will evaluate the efficacy of solengepras as an adjunctive therapy to levodopa and other background PD medications. Read the full press release to learn more about?this?important milestone and potentially transformative therapy for individuals with PD: https://lnkd.in/enxXFJWS

Today marks an exciting milestone for Cerevance with the release of positive data from our Phase 1 study of CVN293, a KCNK13 inhibitor, in healthy volunteers. The findings showed that CVN293 was well-tolerated for up to 14-days of continuous dosing and demonstrated robust brain penetration, supporting its potential advancement to a Phase 2 study. For more details on this important?milestone, read the press release here: https://lnkd.in/eGYWeFmP

Alzheimer’s disease, the most common type of dementia, affects memory, thinking, and behavior. This National Alzheimer’s Awareness Month, join us in raising awareness about this disease. At Cerevance, we are focused on transforming the lives of those with Alzheimer’s through the development of cell-type specific treatments for CNS disorders.

Want to stay updated on the latest in #Parkinsons? Our Phase 2 #ClinicalTrial results for solengepras, featured in The Lancet's eClinicalMedicine, were published in an article by Parkinson's News Today. Read the full story here. https://lnkd.in/e4ximudK

We’re thrilled to announce the publication of our positive Phase 2 data from the clinical trial of solengepras for Parkinson’s disease in The Lancet's eClinicalMedicine. Check out the publication here: https://lnkd.in/eu4nxHZk

Thrilled to welcome, Dr. Sarah Sheikh to our Board of Directors. Her deep expertise in #neuroscience will be an invaluable asset as we continue to advance our mission of transforming the standard of care for CNS disorders. https://shorturl.at/map16

Our CEO, Craig Thompson, recently shared his insights during a panel at the #FierceBiotechSummit, where he discussed the future of #neuroscience innovation. We’re grateful for the opportunity to be a part of this important discussion. Learn more: https://lnkd.in/egyxTVTT

We've achieved our second milestone in our research collaboration with Merck and are excited by the advancements we’ve made in identifying?potential?novel therapeutic targets for patients with Alzheimer’s disease. A huge thank you to our dedicated team and partners at Merck for their hard work and commitment to excellence. Read the press release here: https://lnkd.in/eFFxkMgH